Opportunities for Typhoid Vaccination in India.


Journal

Indian pediatrics
ISSN: 0974-7559
Titre abrégé: Indian Pediatr
Pays: India
ID NLM: 2985062R

Informations de publication

Date de publication:
15 06 2019
Historique:
entrez: 7 7 2019
pubmed: 7 7 2019
medline: 6 2 2020
Statut: ppublish

Résumé

Typhoid fever, an infection with potentially life threatening complications, is responsible for 11 to 21 million illness episodes and 145,000 to 161,000 deaths each year globally. India is a high burden country and also faces the challenge of antimicrobial resistance, which further narrows treatment options. This review analyzes the need for typhoid vaccination in India, and appraises the evidence on efficacy, immunogenicity and cost-effectiveness of currently available typhoid vaccines. In 2018, WHO prequalified the first typhoid conjugate vaccine Vi-TT and recommended it for children aged 6-23 months, along with measles vaccine at 9 or 15 months of age through the expanded programme on immunization. With the high endemicity of typhoid in India and the proven cost-effectiveness of the conjugate vaccine, a roll-out of typhoid vaccine should be considered at the earliest.

Identifiants

pubmed: 31278221

Substances chimiques

Typhoid-Paratyphoid Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

453-458

Auteurs

Manikandan Srinivasan (M)

Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.

Kulandaipalayam Natarajan Sindhu (KN)

Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.

Jacob John (J)

Department of Community Health, Christian Medical College, Vellore, India.

Gagandeep Kang (G)

Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India. Correspondence to: Dr Gagandeep Kang, The Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore 632 002, Tamil Nadu, India. gkang@cmcvellore.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH